sickle cell disease

News

Agios shares slump on sickle cell disease data

Shares in Agios lost nearly half their value after it posted mixed clinical results from a phase 3 trial of its sickle cell disease therapy mitapivat.

News

Pfizer suffers another hit to its GBT sickle cell portfolio

Pfizer's $5.4 billion takeover of Global Blood Therapeutics three years ago is starting to look like a poor deal.

Digital

Enhancing rare disease trials: eCOA technology’s impact on s...

Sickle cell disease (SCD) affects an estimated 20 million people worldwide.

News

Sickle cell gene therapy Casgevy finally cleared for NHS use

Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection.

News

Editas axes two-thirds of its staff, including its CMO

Editas Medicine ends development of its gene-editing therapy for thalassaemia and sickle cell, shedding 65% of staff and narrowing its R&D focus.

News

Beam Therapeutics' chief executive John Evans

Beam points to positive data with key base editing asset

It has been around a year since Beam Therapeutics slashed its headcount and R&D programmes to focus mainly on a sickle cell disease candidate – and the biotech has now revealed the firs

Agios shares slump on sickle cell disease data

Pfizer suffers another hit to its GBT sickle cell portfolio

Enhancing rare disease trials: eCOA technology’s impact on s...

Sickle cell gene therapy Casgevy finally cleared for NHS use

Editas axes two-thirds of its staff, including its CMO

Beam points to positive data with key base editing asset

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

sickle cell disease

Editor's Picks